SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Prenatal exome sequencing and impact on perinatal outcome: cohort study.

Poljak, B; Agarwal, U; Alfirevic, Z; Allen, S; Canham, N; Higgs, J; Kaelin Agten, A; Khalil, A; Roberts, D; Mone, F; et al. Poljak, B; Agarwal, U; Alfirevic, Z; Allen, S; Canham, N; Higgs, J; Kaelin Agten, A; Khalil, A; Roberts, D; Mone, F; Navaratnam, K (2023) Prenatal exome sequencing and impact on perinatal outcome: cohort study. Ultrasound Obstet Gynecol, 61 (3). pp. 339-345. ISSN 1469-0705 https://doi.org/10.1002/uog.26141
SGUL Authors: Khalil, Asma

[img]
Preview
PDF Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (322kB) | Preview
[img] Microsoft Word (.docx) (Supporting information) Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (1MB)

Abstract

OBJECTIVES: First, to determine the uptake of prenatal exome sequencing (pES) and the diagnostic yield of pathogenic (causative) variants in a UK tertiary fetal medicine unit following the introduction of the NHS England Rapid Exome Sequencing Service for fetal anomalies testing (R21 pathway). Second, to identify how the decision to proceed with pES and identification of a causative variant affect perinatal outcomes, specifically late termination of pregnancy (TOP) at or beyond 22 weeks' gestation. METHODS: This was a retrospective cohort study of anomalous fetuses referred to the Liverpool Women's Hospital Fetal Medicine Unit between 1 March 2021 and 28 February 2022. pES was performed as part of the R21 pathway. Trio exome sequencing was performed using an Illumina next-generation sequencing platform assessing coding and splice regions of a panel of 974 prenatally relevant genes and 231 expert reviewed genes. Data on demographics, phenotype, pES result and perinatal outcome were extracted and compared. Descriptive statistics and the χ-square or Fisher's exact test were performed using IBM SPSS version 28.0.1.0. RESULTS: In total, 72 cases were identified and two-thirds of eligible women (n = 48) consented to trio pES. pES was not feasible in one case owing to a low DNA yield and, therefore, was performed in 47 cases. In one-third of cases (n = 24), pES was not proposed or agreed. In 58.3% (14/24) of these cases, this was because invasive testing was declined and, in 41.7% (10/24) of cases, women opted for testing and underwent chromosomal microarray analysis only. The diagnostic yield of pES was 23.4% (11/47). There was no overall difference in the proportion of women who decided to have late TOP in the group in which pES was agreed compared with the group in which pES was not proposed or agreed (25.0% (12/48) vs 25.0% (6/24); P = 1.0). However, the decision to have late TOP was significantly more frequent when a causative variant was detected compared with when pES was uninformative (63.6% (7/11) vs 13.9% (5/36); P < 0.0009). The median turnaround time for results was longer in cases in which a causative variant was identified than in those in which pES was uninformative (22 days (interquartile range (IQR), 19-34) days vs 14 days (IQR, 10-15 days); P < 0.0001). CONCLUSIONS: This study demonstrates the potential impact of identification of a causative variant by pES on decision to have late TOP. As the R21 pathway continues to evolve, we urge clinicians and policymakers to consider introducing earlier screening for anomalies, developing robust guidance for late TOP and ensuring optimized support for couples. © 2022 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.

Item Type: Article
Additional Information: © 2022 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Keywords: R21, exome sequencing, prenatal, termination of pregnancy, Pregnancy, Female, Humans, Cohort Studies, Ultrasonography, Prenatal, Retrospective Studies, Exome Sequencing, Fetus, Prenatal Diagnosis, Fetus, Humans, Ultrasonography, Prenatal, Prenatal Diagnosis, Retrospective Studies, Cohort Studies, Pregnancy, Female, Exome Sequencing, exome sequencing, prenatal, R21, termination of pregnancy, 1114 Paediatrics and Reproductive Medicine, Obstetrics & Reproductive Medicine
SGUL Research Institute / Research Centre: Academic Structure > Molecular and Clinical Sciences Research Institute (MCS)
Journal or Publication Title: Ultrasound Obstet Gynecol
ISSN: 1469-0705
Language: eng
Dates:
DateEvent
1 March 2023Published
12 December 2022Published Online
22 November 2022Accepted
Publisher License: Creative Commons: Attribution-Noncommercial-No Derivative Works 4.0
PubMed ID: 36508432
Web of Science ID: WOS:000959114500006
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/115518
Publisher's version: https://doi.org/10.1002/uog.26141

Actions (login required)

Edit Item Edit Item